Hims & Hers Expands into Multi-Billion Dollar Men’s Health Market

Strategic Pharmaceutical Partnership Announced

Telehealth provider Hims & Hers Health is making a bold strategic move to capture a significant share of the lucrative testosterone therapy market. The company announced a landmark partnership that could unlock substantial new revenue streams beyond its established hair loss and weight management treatments.

On September 10, Hims & Hers revealed an exclusive collaboration with Marius Pharmaceuticals that positions the company to enter a massive underserved market. Beginning in 2026, the platform will offer KYZATREX®, an FDA-approved oral testosterone medication that eliminates the need for injections. Clinical trial data demonstrates impressive efficacy, with testosterone levels restored in up to 96% of treated patients and free testosterone concentrations doubling.